MIDOSTAURIN

Pre-Launch

midostaurin

ANDAORALCAPSULE
Lifecycle
Pre-Launch
Clinical Trials
20

Clinical Trials (5)

NCT04385290Phase 1/2Recruiting

Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)

Started Sep 2020
214 enrolled
Acute Myeloid Leukemia
NCT04027309Phase 3Active Not Recruiting

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Started Dec 2019
777 enrolled
Acute Myeloid LeukemiaMyelodysplastic Syndrome With Excess Blasts-2
NCT03836209Phase 2Active Not Recruiting

Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

Started Dec 2019
181 enrolled
Acute Myeloid Leukemia
NCT03591510Phase 2Active Not Recruiting

A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

Started Mar 2019
22 enrolled
FLT3-mutated Acute Myeloid Leukemia
NCT03207334Phase 2Withdrawn

iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004)

Started Nov 2018
0
Acute Myeloid Leukemia